戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  administered regularly to maintain a steady plasma drug concentration.
2  may cause clinically significant changes in plasma drug concentrations.
3 RI at day 2 correlated with early time point plasma drug concentrations.
4  and insensitive lung cell tumors in vivo at plasma drug concentrations achieved in RA patients under
5                   However, the extremely low plasma drug concentrations achieved, in conjunction with
6 o apparent relationship was observed between plasma drug concentration and clinical response.
7 For the SRI + DEP group, maternal and infant plasma drug concentrations and an estimate of third-trim
8                                              Plasma drug concentrations and bacterial minimum inhibit
9 eveloped that shows sustained maintenance of plasma drug concentrations and drug efficacy for almost
10 , quantitative virologic responses in urine, plasma drug concentrations, and clinical outcome.
11 and associated determinants, PrEP adherence, plasma drug concentrations, and HIV drug resistance in M
12 rug dosage, maternal and infant (cord blood) plasma drug concentrations, and serotonin reuptake inhib
13 round the depot region and was correlated to plasma drug concentration at early time points (0-4days)
14  mice is demonstrated by (1) delivering high plasma drug concentrations for 16 weeks, (2) preventing
15                        The cardiac tissue-to-plasma drug concentration gradient averaged approximatel
16 ity of point-of-care devices able to measure plasma drug concentration in a simple, automated, and co
17                                       Higher plasma drug concentrations in individual patients correl
18 f providing a formulation that could provide plasma drug concentrations in the region of 0.5-1.0ng/mL
19 d with factors that differentially influence plasma drug concentrations in the two disease stages.
20                                              Plasma drug concentration increased dose dependently and
21                                              Plasma drug concentrations measured in Indian children w
22 prolonging drugs with 15 time-matched QT and plasma drug concentration measurements.
23  type 1 (HIV-1) viral load (VL) and multiple plasma drug concentrations measurements to analyze the c
24 of autophagy led to 50-fold increases in the plasma drug concentration of the viral integrase inhibit
25                                              Plasma drug concentrations of both agents were highly va
26                                              Plasma drug concentration peaked at the end of KB infusi
27 tic model to explore the effect of different plasma drug concentration profiles.
28                                        Brain:plasma drug concentration ratios were determined intraop
29  in the treatment of rheumatoid arthritis at plasma drug concentrations substantially higher than are
30 ic AED products may cause greater changes in plasma drug concentrations than generic substitutions of
31                           The area under the plasma drug concentration - time curve for MFG1, MFG2, a
32 ams, and electrocardiographs) and testing of plasma drug concentrations took place during and after c
33 the lower and upper limits, respectively, of plasma drug concentrations used in clinical transplantat
34                                              Plasma drug concentrations were determined over the 13-d
35                                              Plasma drug concentrations were measured by high-perform
36                                              Plasma drug concentrations were undetectable in 92 (97.9
37 e bioavailability of 24 provided efficacious plasma drug concentrations with IP dosing, thus enabling
38 e bioavailability of up to 80% and a maximum plasma drug concentration within 30 min after dosing.